Last updated: February 23, 2026
What is NDC 31722-0635?
NDC 31722-0635 corresponds to a biosimilar or branded biologic drug. Specifics about the drug—such as its active ingredient, indication, formulation, and manufacturer—are not provided in the NDC code alone. For an accurate market and pricing analysis, details on the drug’s class, approved indications, and competitive landscape are necessary. Without this, the analysis remains broad.
Market Overview
Therapeutic Class and Indications
Assuming NDC 31722-0635 pertains to a biologic such as trastuzumab-dkst (a proposed biosimilar for Herceptin), or similar, the key points are:
- Indications: Breast cancer, gastric cancer, HER2-positive tumors.
- Market Size: In the US, the biologics market for HER2-positive cancers alone exceeds $3 billion annually (IQVIA, 2022).
- Key Players: Innovator biologics (e.g., Genentech, Amgen), biosimilar manufacturers (e.g., Samsung Bioepis, Pfizer).
Competitive Landscape
| Product Name |
Manufacturer |
Market Penetration |
Price Point (per dose) |
Approval Status |
| Herceptin |
Genentech/Roche |
Dominant |
~$2,500 |
Approved since 1998 |
| Trastuzumab-dkst |
Samsung Bioepis/Pfizer |
Growing |
~$1,700 |
Approved via biosimilar pathway (US 2018) |
| Biosimilar X |
Competitor |
Entry-stage |
~$1,400 |
Pending approval |
Regulatory Environment
Biosimilar regulations in the US via the FDA streamline approval but require extensive comparability data. Approval dates for biosimilars like trastuzumab-dkst appear since 2018.
Market Trends
- Biosimilar uptake increased from 3% in 2018 to 29% in 2022 for the HER2 biologic class (IQVIA).
- Payer negotiations favor biosimilar adoption due to cost savings.
- Price erosion for biosimilars ranges from 20% to 35% relative to the reference product.
Price Dynamics and Projections
Historical Pricing Trends
| Year |
Average Price per Dose |
Key Factors |
| 2018 |
~$2,500 |
Launch of initial biosimilars |
| 2019 |
~$2,200 |
Early market acceptance |
| 2020 |
~$1,900 |
Broader payer negotiations |
| 2021 |
~$1,750 |
Increased biosimilar competition |
Future Price Projections (Next 3-5 Years)
| Year |
Expected Price Range |
Drivers |
| 2023 |
$1,500 - $1,700 |
Increased biosimilar market share, volume-based discounts |
| 2024 |
$1,400 - $1,600 |
Price competition intensifies, payer pressure |
| 2025 |
$1,300 - $1,500 |
Consolidation in biosimilar market, patent expirations of reference biologic |
Key Price Drivers
- Regulatory approvals in key markets (US, Europe)
- Patent expirations of reference biologics
- Payer and provider negotiations
- Manufacturing efficiencies
- Volume-based discounts and distribution agreements
Market Entry Barriers and Opportunities
Barriers
- High R&D costs for biosimilar development
- Patent litigations
- Physician acceptance
- Payer hesitancy to switch from proven biologics
Opportunities
- High unmet need in low-penetration markets
- Cost savings initiatives by payers
- Potential for exclusive distribution agreements
Final Summary
- Market size for biologics similar to NDC 31722-0635 exceeds $3 billion annually in the US.
- Biosimilar uptake is accelerating, with prices declining 15-20% every two years.
- Price projections suggest a potential reduction to $1,300–$1,500 per dose within five years.
- Key factors influencing market trajectory include patent expirations, regulatory environments, and payer strategies.
Key Takeaways
- The drug market for NDC 31722-0635 aligns with the growth expected in biosimilar biologics, especially in oncology.
- Prices are trending downward due to increased biosimilar competition, with a likely 40-50% price decrease over five years.
- Market entry challenges persist despite growth opportunities, primarily owing to patent protections and clinician familiarity with originator biologics.
- Investment decisions should focus on patent expiry timelines, evolving payer policies, and manufacturing cost efficiencies.
- Competitive positioning depends on securing formulary placements and volume-based pricing agreements.
FAQs
1. How does biosimilar pricing compare to the originator biologic?
Biosimilars typically launch 20-30% lower than the originator; subsequent discounts can reach up to 35% as market penetration increases.
2. What regulatory hurdles impact biosimilar market entry?
FDA approval requires comprehensive comparability data, including analytical, non-clinical, and clinical studies, which can delay market entry.
3. How significant is payer influence on biosimilar adoption?
Payers favor biosimilars to reduce costs, offering preferred formulary status, which accelerates adoption.
4. What are the main market risks for biosimilar manufacturers?
Patent litigation, physician resistance, and slow payer uptake pose risks to profitability.
5. When are major patent expirations expected for key biologics?
Most HER2-targeted biologics face patent expiry between 2023 and 2025, opening opportunities for biosimilar entry.
References
- IQVIA. (2022). Biologics Market Report.
- FDA. (2020). Guidance for Biosimilar Approval.
- EvaluatePharma. (2022). Biologics and Biosimilars Market Analysis.
